Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...
EQS-News: ABIVAX / Key word (s): Annual Results Abivax Announces Full Year 2024 Financial Results 24.03.2025 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback